AbbVie

AbbVie supports higher education access for students living with chronic inflammatory diseases through the AbbVie Immunology Scholarship, a national program for the 2026-2027 academic year. The program serves U.S. citizens and legal permanent residents who plan to enroll full time at accredited two-year or four-year colleges, universities, or vocational-technical schools in the United States, including students pursuing certificate, associate, bachelor’s, master’s, and Ph.D. pathways. Its stated audience includes students diagnosed by a healthcare professional with conditions such as ankylosing spondylitis, atopic dermatitis, Crohn’s disease, giant cell arteritis, hidradenitis suppurativa, juvenile idiopathic arthritis, juvenile psoriatic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and uveitis. The organization’s scholarship support is structured around substantial multi-level awards: $10,000 for associate degree study and $20,000 for bachelor’s, master’s, and Ph.D. study. Awards are renewable for up to three additional years, or until a bachelor’s or graduate degree is earned, for recipients who maintain a minimum 3.0 cumulative GPA on a 4.0 scale and remain enrolled full time. Recipient selection emphasizes community involvement, academic performance, and the ability to serve as a positive role model in the immunology community. AbbVie also sets clear eligibility boundaries for this program. Employees of AbbVie and their immediate family members are excluded, as are patients contracted through Patient Health Perspectives and healthcare providers and their immediate family members. The scholarship’s rules further state that use of any AbbVie medicine or product is not a factor in recipient selection. For this cycle, applications are open nationally with a deadline of April 30, 2026 at 3:00 PM CT, underscoring AbbVie’s role in directing education support to students managing serious chronic inflammatory conditions while pursuing postsecondary and graduate study.